Evidence map›Paper›PMID 41458200›Full record

ArticleChina CDC weekly2025

Technical and Implementation Guidelines for the Introduction of Human Papillomavirus Vaccine into China's National Immunization Program.

Fuzhen Wang, Lei Cao, Keli Li, Guomin Zhang, Lixin Hao, Chao Ma, Ning Wen, Xiaoxue Liu, Jiakai Ye, Yan Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fuzhen WangNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Lei CaoNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Keli LiNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Guomin ZhangNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Lixin HaoNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Chao MaNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Ning WenNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Xiaoxue LiuNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Jiakai YeNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Yan LiNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Yudan SongNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Zhijie AnNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Wenzhou YuNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.
Zundong YinNational Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human papillomavirus (HPV) vaccination administered before viral exposure (i.e., prior to sexual debut) effectively prevents infection with vaccine-type HPV strains and associated diseases, including cervical cancer. To advance HPV vaccination efforts and cervical cancer prevention, China has incorporated the bivalent HPV vaccine (types 16/18) into its National Immunization Program (NIP) as a program vaccine. This Policy Note presents comprehensive technical and implementation guidelines for HPV vaccine deployment, encompassing guidance development methodology, target population definition, routine vaccination schedules, catch-up vaccination protocols, implementation strategies, vaccine coverage and adverse event monitoring plans, and anticipated implementation challenges with proposed mitigation measures. The Vaccine Technical Working Groups of the China CDC developed relevant technical recommendations and guidelines, which were officially issued in November 2025.

Indexed as

guidelinesHPVnational immunization programvaccine

Identifiers

PMID41458200
PMCPMC12739462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.